Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Russell Warnick

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Clinical Chemistry|January 27, 2009
Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best PracticesJohn H Contois, Joseph P McConnell, Amar A Sethi, et al.
Preventive Cardiology|July 20, 2006
Lipoprotein-associated phospholipase A2: review and recommendation of a clinical cut point for adultsRichard B Lanman, Robert L Wolfert, James K Fleming, et al.
Journal of Clinical Lipidology|December 16, 2014
Lipoprotein(a) mass: a massively misunderstood metricJoseph P McConnell, Philip A Guadagno, Thomas D Dayspring, et al.
Journal of Cardiovascular Translational Research|March 6, 2014
Does APOE genotype modify the relations between serum lipid and erythrocyte omega-3 fatty acid levels?William S Harris, James V Pottala, Dawn L Thiselton, et al.
Journal of Clinical Lipidology|April 26, 2015
Discordance between apolipoprotein B and low-density lipoprotein particle number is associated with insulin resistance in clinical practiceStephen A Varvel, Thomas D Dayspring, Yvette Edmonds, et al.
Journal of Cardiovascular Translational Research|July 30, 2014
Comprehensive biomarker testing of glycemia, insulin resistance, and beta cell function has greater sensitivity to detect diabetes risk than fasting glucose and HbA1c and is associated with improved glycemic control in clinical practiceStephen A Varvel, Szilard Voros, Dawn L Thiselton, et al.
BMJ Open Diabetes Research & Care|December 3, 2014
Serum α-hydroxybutyrate (α-HB) predicts elevated 1 h glucose levels and early-phase β-cell dysfunction during OGTTStephen A Varvel, James V Pottala, Dawn L Thiselton, et al.
Clinical Chemistry|February 7, 2013
Association of apolipoprotein B and nuclear magnetic resonance spectroscopy-derived LDL particle number with outcomes in 25 clinical studies: assessment by the AACC Lipoprotein and Vascular Diseases Division Working Group on Best Practices, Thomas G Cole, John H Contois, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|December 3, 2014
Validation of a lipoprotein(a) particle concentration assay by quantitative lipoprotein immunofixation electrophoresisPhilip A Guadagno, Erin G Summers Bellin, William S Harris, et al.
Clinical Chemistry|January 24, 2002
Assessment and recommendations on factors contributing to preanalytical variability of urinary pyridinoline and deoxypyridinolineHubert W Vesper, Laurence M Demers, Richard Eastell, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Clinical Chemistry|January 27, 2009
Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best PracticesJohn H Contois, Joseph P McConnell, Amar A Sethi, et al.
Preventive Cardiology|July 20, 2006
Lipoprotein-associated phospholipase A2: review and recommendation of a clinical cut point for adultsRichard B Lanman, Robert L Wolfert, James K Fleming, et al.
Journal of Clinical Lipidology|December 16, 2014
Lipoprotein(a) mass: a massively misunderstood metricJoseph P McConnell, Philip A Guadagno, Thomas D Dayspring, et al.
Journal of Cardiovascular Translational Research|March 6, 2014
Does APOE genotype modify the relations between serum lipid and erythrocyte omega-3 fatty acid levels?William S Harris, James V Pottala, Dawn L Thiselton, et al.
Journal of Clinical Lipidology|April 26, 2015
Discordance between apolipoprotein B and low-density lipoprotein particle number is associated with insulin resistance in clinical practiceStephen A Varvel, Thomas D Dayspring, Yvette Edmonds, et al.
Journal of Cardiovascular Translational Research|July 30, 2014
Comprehensive biomarker testing of glycemia, insulin resistance, and beta cell function has greater sensitivity to detect diabetes risk than fasting glucose and HbA1c and is associated with improved glycemic control in clinical practiceStephen A Varvel, Szilard Voros, Dawn L Thiselton, et al.
BMJ Open Diabetes Research & Care|December 3, 2014
Serum α-hydroxybutyrate (α-HB) predicts elevated 1 h glucose levels and early-phase β-cell dysfunction during OGTTStephen A Varvel, James V Pottala, Dawn L Thiselton, et al.
Clinical Chemistry|February 7, 2013
Association of apolipoprotein B and nuclear magnetic resonance spectroscopy-derived LDL particle number with outcomes in 25 clinical studies: assessment by the AACC Lipoprotein and Vascular Diseases Division Working Group on Best Practices, Thomas G Cole, John H Contois, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|December 3, 2014
Validation of a lipoprotein(a) particle concentration assay by quantitative lipoprotein immunofixation electrophoresisPhilip A Guadagno, Erin G Summers Bellin, William S Harris, et al.
Clinical Chemistry|January 24, 2002
Assessment and recommendations on factors contributing to preanalytical variability of urinary pyridinoline and deoxypyridinolineHubert W Vesper, Laurence M Demers, Richard Eastell, et al.
Pageof 3